ClinicalTrials.gg
CompletedNCT06060457Updated Jul 30, 2025Results posted

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

A Phase 3 interventional study of Placebo and mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 34 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,900
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.

Enrollment
3rd of 10
1,900 · median 579
Started
2023
with 3 others
Phase 3
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
10 of 10
ModernaTX, Inc.

Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 3rd largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 3, and was the 6th registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →

About mRNA-1345 respiratory syncytial virus vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age. The study will examine the impact of Fluzone HD on the immune response to mRNA-1345 against RSV-A and RSV-B, as well as the impact of mRNA-1345 on the immune response to Fluzone HD against 4 vaccine-matched Influenza A and B strains.

03

Conditions studied

  • Respiratory Syncytial Virus

Browse trials for

Keywords

  • Viral Diseases
  • Messenger RNA
  • Moderna
  • mRNA-1345
  • Respiratory syncytial virus
  • Vaccines
  • RSV Vaccine
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:

    • Absence of changes in medical therapy within 60 days of Day 1 due to treatment failure or toxicity,
    • Absence of serious or significant medical events within 30 days of Day 1, and
    • Absence of known, current, and life-limiting diagnoses which, in the opinion of the Investigator, would make completion of the protocol unlikely.
  • A participant assigned female at birth is eligible to participate if they are or not a person of .

Key Exclusion Criteria:

  • Close contact with someone with laboratory-confirmed influenza and/or RSV infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to Day 1.
  • Reported history of congenital or acquired immunodeficiency, condition or immune-mediated disease, asplenia, or recurrent severe infections.
  • Participant has tested positive for influenza or RSV by local health authority-approved testing methods ≤6 months prior to Day 1.
  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections (Day 1 and Day 22) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after study injections.
  • Participant has received a seasonal influenza vaccine or any other influenza vaccine ≤6 months prior to Day 1.
  • Participant has received any RSV vaccine (authorized/approved by local health agency or investigational) prior to Day 1.

Note: Other protocol-defined inclusion and/or exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,900 participants (actual)

Study arms

  • Experimental
    Fluzone HD + mRNA-1345

    Participants will receive Fluzone HD + mRNA-1345 by intramuscular (IM) injection on Day 1 followed by placebo by IM injection on Day 22.

    Biological: Placebo · Biological: mRNA-1345 · Biological: Fluzone HD

  • Experimental
    Fluzone HD Followed by mRNA-1345

    Participants will receive Fluzone HD + placebo by IM injection on Day 1 followed by mRNA-1345 by IM injection on Day 22.

    Biological: Placebo · Biological: mRNA-1345 · Biological: Fluzone HD

Interventions

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

  • BiologicalmRNA-1345

    Suspension for injection

  • BiologicalFluzone HD

    Suspension for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection

    Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Within 7 days after Day 1 injection

  2. Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection

    Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Within 7 days after Day 22 injection

  3. Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 21 days after Day 1 injection

  4. Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 21 days after Day 22 injection

  5. Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

    A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 202

  6. Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs)

    Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.

    Time frame: Day 22 (for Arm 1) and Day 43 (for Arm 2)

  7. GMT of Serum Anti-Hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.

    Time frame: Day 22

Secondary outcomes

  1. Percentage of Participants With Seroresponse for RSV-A and RSV-B nAbs, as Measured by HAI Assay

    Seroresponse at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.

    Time frame: Baseline to Day 22 (for Arm 1) or Day 43 (for Arm 2)

  2. Geometric Mean Fold-Rise (GMFR) of Postinjection RSV-A and RSV-B nAbs Antibodies for Influenza, as Measured by HAI Assay

    95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 22 (for Arm 1) or Day 43 (for Arm 2)

  3. Percentage of Participants With ≥2-fold Increase in RSV-A and RSV-B nAbs

    ≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.

    Time frame: Day 22 (Arm 1) or Day 43 (Arm 2)

  4. Percentage of Participants With Seroconversion, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Seroconversion at a participant level was defined as a titer ≥1:40 if baseline is \< 1:10 or at least a 4-fold increase from baseline if baseline was ≥1:10. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.

    Time frame: Day 22

  5. GMFR of Serum Ab Level, as Measured by HAI Assay

    95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 22

Other outcomes

  1. Number of Deaths Related to Study Drug

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

    Time frame: Day 1 through Day 202

07

Results

Posted Jul 30, 2025

Participant flow

Participant flow — Overall Study
MilestoneFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Started950950
Received day 1 injection946947
Received day 22 injection919911
Safety set947946
Completed914909
Not completed3641
Withdrew: Adverse event11
Withdrew: Death22
Withdrew: Lost to follow-up1719
Withdrew: Physician decision01
Withdrew: Protocol violation11
Withdrew: Serious adverse reaction (sar)/reactogenicity event11
Withdrew: Withdrawal by subject1215
Withdrew: Other than specified21

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Within 7 days after Day 1 injection
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
ParticipantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection689547
PrimaryNumber of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Within 7 days after Day 22 injection
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection
ParticipantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection251557
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 21 days after Day 1 injection
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection
ParticipantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection7272
PrimaryNumber of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 21 days after Day 22 injection
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection
ParticipantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection6071
PrimaryNumber of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 202
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
ParticipantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
MAAEs194191
AESIs01
SAEs2333
AEs Leading to Discontinuation33
PrimaryGeometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs)

Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.

Time frame:
Day 22 (for Arm 1) and Day 43 (for Arm 2)
Reported as:
Geometric mean · IU/mL
Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs)
IU/mLFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
RSV-A11800.26 (11063.69 to 12585.87)18874.12 (17670.37 to 20159.87)
RSV-B4197.74 (3949.53 to 4461.54)6579.15 (6178.21 to 7006.11)
Statistical analysis
  • Fluzone HD + mRNA-1345 Followed by Placebo vs Fluzone HD + Placebo Followed by mRNA-1345 · Geometric mean ratio (gmr): 0.625 · 95% CI 0.570 to 0.686
  • Fluzone HD + mRNA-1345 Followed by Placebo vs Fluzone HD + Placebo Followed by mRNA-1345 · Gmr: 0.638 · 95% CI 0.584 to 0.697
PrimaryGMT of Serum Anti-Hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.

Time frame:
Day 22
Reported as:
Geometric mean · titer
GMT of Serum Anti-Hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay
titerFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Influenza A H1N1 Antibody108.11 (99.76 to 117.15)124.15 (114.49 to 134.62)
Influenza A H3N2 Antibody198.53 (183.61 to 214.67)228.83 (211.50 to 247.58)
Influenza B Austria Antibody105.32 (98.34 to 112.80)118.27 (110.37 to 126.74)
Influenza B Phuket Antibody33.17 (31.28 to 35.17)34.97 (32.97 to 37.10)
SecondaryPercentage of Participants With Seroresponse for RSV-A and RSV-B nAbs, as Measured by HAI Assay

Seroresponse at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.

Time frame:
Baseline to Day 22 (for Arm 1) or Day 43 (for Arm 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Seroresponse for RSV-A and RSV-B nAbs, as Measured by HAI Assay
percentage of participantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
RSV-A64.7 (61.4 to 67.8)78.2 (75.3 to 80.9)
RSV-B48.7 (45.3 to 52.0)61.9 (58.5 to 65.2)
SecondaryGeometric Mean Fold-Rise (GMFR) of Postinjection RSV-A and RSV-B nAbs Antibodies for Influenza, as Measured by HAI Assay

95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 22 (for Arm 1) or Day 43 (for Arm 2)
Reported as:
Geometric mean · ratio
Geometric Mean Fold-Rise (GMFR) of Postinjection RSV-A and RSV-B nAbs Antibodies for Influenza, as Measured by HAI Assay
ratioFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
RSV-A6.49 (6.03 to 6.99)10.00 (9.25 to 10.82)
RSV-B4.08 (3.81 to 4.36)5.92 (5.48 to 6.39)
SecondaryPercentage of Participants With ≥2-fold Increase in RSV-A and RSV-B nAbs

≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.

Time frame:
Day 22 (Arm 1) or Day 43 (Arm 2)
Reported as:
Number · percentage of participants
Percentage of Participants With ≥2-fold Increase in RSV-A and RSV-B nAbs
percentage of participantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
RSV-A85.4 (82.9 to 87.6)93.2 (91.3 to 94.8)
RSV-B75.4 (72.5 to 78.2)83.5 (80.8 to 85.9)
SecondaryPercentage of Participants With Seroconversion, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Seroconversion at a participant level was defined as a titer ≥1:40 if baseline is \< 1:10 or at least a 4-fold increase from baseline if baseline was ≥1:10. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.

Time frame:
Day 22
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion, as Measured by HAI Assay
percentage of participantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Influenza A H1N1 Antibody56.0 (52.7 to 59.3)59.0 (55.6 to 62.2)
Influenza A H3N2 Antibody60.3 (57.0 to 63.5)65.8 (62.6 to 68.9)
Influenza B Austria Antibody55.5 (52.2 to 58.8)59.1 (55.8 to 62.4)
Influenza B Phuket Antibody31.7 (28.6 to 34.8)32.8 (29.7 to 36.1)
SecondaryGMFR of Serum Ab Level, as Measured by HAI Assay

95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 22
Reported as:
Geometric mean · ratio
GMFR of Serum Ab Level, as Measured by HAI Assay
ratioFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Influenza A H1N1 Antibody5.21 (4.76 to 5.71)5.78 (5.25 to 6.36)
Influenza A H3N2 Antibody6.20 (5.64 to 6.82)7.16 (6.49 to 7.89)
Influenza B Austria Antibody4.87 (4.48 to 5.30)5.64 (5.17 to 6.16)
Influenza B Phuket Antibody2.73 (2.56 to 2.90)2.88 (2.70 to 3.07)
Other pre-specifiedNumber of Deaths Related to Study Drug

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

Time frame:
Day 1 through Day 202
Reported as:
Count of participants · Participants
Number of Deaths Related to Study Drug
ParticipantsFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
Deaths22
Deaths related to study drug00

Adverse events

Collected over All-cause mortality and serious adverse events were collected Day 1 up to Day 202. Other (not including serious) unsolicited adverse events were collected up to 21 days after each study injection (that is, Day 1 up to Day 21 for the first injection and Day 22 up to Day 43 for the second injection).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluzone HD + mRNA-1345 Followed by Placebo2/950 (0.2%)23/947 (2.4%)0/947 (0%)
Fluzone HD + Placebo Followed by mRNA-13452/950 (0.2%)33/946 (3.5%)0/946 (0%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventFluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345
PneumoniaInfections and infestations2/9473/946
Angina unstableCardiac disorders0/9472/946
Atrial fibrillationCardiac disorders2/9472/946
Coronary artery diseaseCardiac disorders0/9472/946
BradycardiaCardiac disorders2/9470/946
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/9471/946
Pleural effusionRespiratory, thoracic and mediastinal disorders2/9470/946
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/9471/946
Bacterial sepsisInfections and infestations0/9471/946
COVID-19Infections and infestations0/9471/946

Baseline characteristics

The Randomized Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study.

Age, Continuous
Age, Continuous(years)Fluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345Total
Mean70.7 ± 4.8070.7 ± 4.8070.7 ± 4.80
Sex: Female, Male
Sex: Female, Male(Participants)Fluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345Total
Female5485301078
Male402420822
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345Total
Hispanic or Latino209222431
Not Hispanic or Latino7287221450
Unknown or Not Reported13619
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fluzone HD + mRNA-1345 Followed by PlaceboFluzone HD + Placebo Followed by mRNA-1345Total
American Indian or Alaska Native729
Asian131225
Native Hawaiian or Other Pacific Islander011
Black or African American187191378
White7357381473
More than one race7310
Unknown or Not Reported134
08

Study locations

34 sites
  • Scottsdale Clinical Trials
    Scottsdale, Arizona 85258, United States
  • Headlands Research, Inc.
    Scottsdale, Arizona 85260, United States
  • West Coast Research LLC
    Dublin, California 94568, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Peninsula Research Associates (PRA)
    Rolling Hills Estates, California 90274, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Neoclinical Research
    Hialeah, Florida 33016, United States
  • Health Awareness INC
    Jupiter, Florida 33458, United States
  • South Florida Research Center, Inc.
    Miami, Florida 33135, United States
  • Suncoast Research Associates, LLC
    Miami, Florida 33173, United States
  • Headlands Research - Orlando
    Orlando, Florida 32819, United States
  • New Tampa Health, Inc
    Tampa, Florida 33603, United States
  • Clinical Research Atlanta/Headlands
    Stockbridge, Georgia 30281, United States
  • Bingham Memorial Hospital
    Blackfoot, Idaho 83221, United States
  • DM Clinical Research- River Forest
    River Forest, Illinois 60305, United States
  • Velocity Clinical Research-Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • DelRicht Research @ Neighborhood Health
    Prairieville, Louisiana 70769, United States
  • DM Clinical Research - Brookline
    Brookline, Massachusetts 02445, United States
  • DM Clinical Research - Southfield
    Southfield, Michigan 48076, United States
  • Delricht Research at Gulfport Memorial
    Gulfport, Mississippi 39503, United States
  • Delricht Research
    Springfield, Missouri 65807, United States
  • Be Well Clinical Studies, LLC
    Lincoln, Nebraska 68516, United States
  • Velocity Clinical Research-Norfolk
    Norfolk, Nebraska 68701, United States
  • Trial Management Associates, LLC
    Wilmington, North Carolina 28403, United States
  • Synexus AES - Akron
    Akron, Ohio 44311, United States
  • Centricity Research
    Columbus, Ohio 43213, United States
  • Delricht Tate
    Tulsa, Oklahoma 74133, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Delricht Moyer
    Hendersonville, Tennessee 37075, United States
  • DM Clinical Research - Houston
    Houston, Texas 77065, United States
  • DELRICHT RESEARCH at ZOMNIR FAMILY MEDICINE
    McKinney, Texas 75070, United States
  • Javara Inc. /Privia Medical Group Gulf Coast, PLLC
    Sugar Land, Texas 77054, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
09

References and documents

Publications

  • Comstock E, Fogarty C, Caso J, Vu J, Sinha A, Cao X, Chen H, Rushton L, Ma C, Priddy F. Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial. Hum Vaccin Immunother. 2026 Dec;22(1):2649335. doi: 10.1080/21645515.2026.2649335. Epub 2026 Apr 28. PubMed 42048601 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jun 2024, 8 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 8 months is below that.

Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2023
First posted
Sep 29, 2023
StartActual
Sep 25, 2023
Primary completionActual
Jun 7, 2024
CompletionActual
Jun 7, 2024
Results first posted
Jul 30, 2025
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06060457
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Sep 25, 2023
Primary completion
Jun 7, 2024
Completion
Jun 7, 2024
Results posted
Jul 30, 2025
Last update
Jul 30, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine

Start the discussion